We have studied the effect of glycosylation on influenza virus major membrane glycoprotein hemagglutinin (HA) with regards to its role in receptor binding and immune response, and developed a new strategy for molecular vaccine design. Monoglycosylated HA is found to be a cross-strain vaccine against various influenza virus infections. In addition, glyco-engineering has been applied to the N-glycans on the Fc domain of an anti-influenza broadly neutralizing antibody FI6. This glyco-engineered FI6 (FI6m) was found to have the effector function of enhanced antibody-dependent cellular cytotoxicity. When injected prophylactically, FI6m can protect mice from lethal dose challenge of H1N1 influenza virus. Structural study of a homogeneous IgG-Fc glycoform with N-glycan designed to maximize the antibody dependent cellular cytotoxicity will be presented.

Influenza vaccine and ADCC

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.